Teva Pharmaceutical Industries (TEVA) - Investment Analysts' Recent Ratings Changes


According to Zacks, "Teva's first quarter results were strong with the company beating on earnings and revenues. Strength in the specialty business helped offset weakness in the generics segment that didn't see any major launches during the quarter.



from Biotech News